Literature DB >> 21532809

Ingredients for success: a familial cancer clinic in an oncology practice setting.

Paul R Duncan1, James T Lin.   

Abstract

PURPOSE: Genetic cancer risk assessment (GCRA) has become increasingly important in clinical cancer care. Almost all published information on genetic risk assessment has come from academic institutions. However, a majority of patients with cancer are seen in the community practice setting.
METHODS: We describe the evolution of a community oncology practice GCRA clinic.
RESULTS: Over a 10-year period, 445 patients were seen for a possible genetic cancer syndrome. This included 325 patients with family history of breast or ovarian cancer, 92 patients with family history of colorectal cancer or polyposis, and 28 families with another familial cancer predisposition. Fifty-three unique families with a genetic mutation were identified.
CONCLUSION: A GCRA clinic can be incorporated into an oncology practice setting and can enhance the standard of care for the entire community. We present data reflecting a 10-year experience with such a clinic and provide recommendations for establishing a successful one.

Entities:  

Year:  2011        PMID: 21532809      PMCID: PMC3014509          DOI: 10.1200/JOP.2010.000048

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  25 in total

1.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

2.  Concise handbook of familial cancer susceptibility syndromes - second edition.

Authors:  Noralane M Lindor; Mary L McMaster; Carl J Lindor; Mark H Greene
Journal:  J Natl Cancer Inst Monogr       Date:  2008

Review 3.  Ethical and legal aspects of cancer genetic testing.

Authors:  Kenneth Offit; Peter Thom
Journal:  Semin Oncol       Date:  2007-10       Impact factor: 4.929

4.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

5.  Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership.

Authors:  Deborah J MacDonald; Kathleen R Blazer; Jeffrey N Weitzel
Journal:  J Natl Compr Canc Netw       Date:  2010-05       Impact factor: 11.908

6.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.

Authors:  David E Goldgar; Douglas F Easton; Graham B Byrnes; Amanda B Spurdle; Edwin S Iversen; Marc S Greenblatt
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

Review 7.  Strategies for identifying hereditary nonpolyposis colon cancer.

Authors:  D Gareth Evans; Sheila Walsh; James Hill; Raymond T McMahon
Journal:  Semin Oncol       Date:  2007-10       Impact factor: 4.929

8.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

Review 9.  Hereditary colorectal cancer: MYH-associated polyposis and other newly identified disorders.

Authors:  Noralane M Lindor
Journal:  Best Pract Res Clin Gastroenterol       Date:  2009       Impact factor: 3.043

10.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Authors:  Noah D Kauff; Susan M Domchek; Tara M Friebel; Mark E Robson; Johanna Lee; Judy E Garber; Claudine Isaacs; D Gareth Evans; Henry Lynch; Rosalind A Eeles; Susan L Neuhausen; Mary B Daly; Ellen Matloff; Joanne L Blum; Paul Sabbatini; Richard R Barakat; Clifford Hudis; Larry Norton; Kenneth Offit; Timothy R Rebbeck
Journal:  J Clin Oncol       Date:  2008-02-11       Impact factor: 44.544

View more
  3 in total

1.  Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations.

Authors:  Yael Laitman; Bing-Jian Feng; Itay M Zamir; Jeffrey N Weitzel; Paul Duncan; Danielle Port; Eswary Thirthagiri; Soo-Hwang Teo; Gareth Evans; Ayse Latif; William G Newman; Ruth Gershoni-Baruch; Jamal Zidan; Shani Shimon-Paluch; David Goldgar; Eitan Friedman
Journal:  Eur J Hum Genet       Date:  2012-07-04       Impact factor: 4.246

Review 2.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

Review 3.  Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States.

Authors:  Deborah Cragun; Tuya Pal
Journal:  ISRN Oncol       Date:  2013-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.